A 21-year experience with major hemorrhage after percutaneous liver biopsy.
Nine thousand two hundred twelve liver biopsies were performed according to a defined protocol, and data were prospectively recorded to identify risk factors for major bleeding. There were 10 fatal and 22 nonfatal hemorrhages (0.11% and 0.24%, respectively). By comparison with a control group that did not hemorrhage, malignancy, age, sex, and the number of passes were the only predictable risk factors. The risk of fatal hemorrhage in patients with malignancy is estimated to be 0.4%; for nonfatal hemorrhage, 0.57%. In patients undergoing liver biopsy for nonmalignant disease, the risks are 0.04% and 0.16%, respectively.
McGill
D B
DB
Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Rakela
J
J
Zinsmeister
A R
AR
Ott
B J
BJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D001707:Biopsy, Needle / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D008099:Liver / Q000473:pathology*; D008107:Liver Diseases / Q000150:complications / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012307:Risk Factors